Press Releases

06.12.2018

Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate World’s Leading Infectious Cause of Blindness

06.07.2018

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation

06.04.2018

Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations

06.04.2018

Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)

06.01.2018

Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

05.31.2018

Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress

05.30.2018

Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis

05.30.2018

The Pfizer Foundation Announces $5 Million in Grants to Support Women and Families

05.29.2018

Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications

05.23.2018

FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy

05.22.2018

A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+

05.22.2018

Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine